{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:03:15Z","timestamp":1791932595306,"version":"4.3.4"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":851,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Therapy choices in relapsed\/refractory multiple myeloma (RRMM) should consider patient satisfaction with treatment, because it is associated with adherence to therapy, health outcomes, and medical safety. The primary objective of this pilot cross-sectional observational study was to ascertain factors associated with patient-reported treatment satisfaction in RRMM.<\/jats:p>\n <\/jats:sec>\n \n Patients and Methods<\/jats:title>\n Patients with a self-reported diagnosis of RRMM recruited from PatientsLikeMe, MyelomaCrowd, and Facebook were administered an electronic survey that included questions on demographics and clinical history, treatment experience, economic burden, and standardized patient-reported outcome measures, including the Treatment Satisfaction Questionnaire for Medication, Eastern Cooperative Oncology Group performance status (ECOG PS) measure, and Work Productivity and Activity Impairment Questionnaire: Specific Health Problem V2.0. Univariable and multivariable analyses were used to identify predictors of patient-perceived treatment satisfaction.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n One hundred sixty patients with RRMM participated in the study, with a median of two prior relapses and 66.3% reporting the most recent relapse within the last 12 months. ECOG PS \u22652 was associated with lower patient-reported global satisfaction and perceived effectiveness of current treatment. In addition to shorter time spent receiving therapy, orally administered treatment was the strongest predictor of higher satisfaction with treatment convenience. For patients receiving an injectable drug-containing regimen versus an all-oral regimen, respectively, time spent receiving multiple myeloma-directed therapy was higher (12.6 vs. 4.0 hours per month), and total monthly indirect costs were $1,033 and $241.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Poor ECOG PS was linked to reduced treatment satisfaction and perceived effectiveness of current therapy, whereas an all-oral regimen was associated with increased treatment convenience satisfaction.<\/jats:p>\n <\/jats:sec>\n \n Implications for Practice<\/jats:title>\n This study suggests that attributes including better Eastern Cooperative Oncology Group performance status, less time spent receiving treatment, and oral route of treatment administration lead to higher patient-perceived satisfaction with relapsed\/refractory multiple myeloma (RRMM) treatment. Oral route of administration was also associated with less time spent receiving treatment and reduced economic burden for patients. Increased attention to these factors in shared treatment decision making is warranted to help identify individual patient needs, preferences, and expectations for RRMM treatments, to resolve dissatisfaction issues, and to improve the experience of patients with RRMM.<\/jats:p>\n <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0724","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T18:35:12Z","timestamp":1564684512000},"page":"1479-1487","source":"Crossref","is-referenced-by-count":32,"title":["Patient-Reported Factors in Treatment Satisfaction in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)"],"prefix":"10.1093","volume":"24","author":[{"given":"Ajai","family":"Chari","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Romanus","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pronabesh","family":"DasMahapatra","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hoole","sequence":"additional","affiliation":[{"name":"PatientsLikeMe, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lowe","sequence":"additional","affiliation":[{"name":"PatientsLikeMe, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Curran","sequence":"additional","affiliation":[{"name":"PatientsLikeMe, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Campbell","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill A.","family":"Bell","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"key":"2021122508044100900_onco13054-bib-0001","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival","volume":"101","author":"Turesson","year":"2018","journal-title":"Eur J Haematol"},{"key":"2021122508044100900_onco13054-bib-0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2021122508044100900_onco13054-bib-0003","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"R\u00f6llig","year":"2015","journal-title":"Lancet"},{"key":"2021122508044100900_onco13054-bib-0004","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2017","journal-title":"Leukemia"},{"key":"2021122508044100900_onco13054-bib-0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11864-014-0276-6","article-title":"New approaches to management of multiple myeloma","volume":"15","author":"Genadieva-Stavric","year":"2014","journal-title":"Curr Treat Options Oncol"},{"key":"2021122508044100900_onco13054-bib-0006","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/17474086.2017.1285694","article-title":"Triplet combinations in relapsed\/refractory myeloma: Update on recent phase 3 trials","volume":"10","author":"Boudreault","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"2021122508044100900_onco13054-bib-0007","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00520-018-4137-x","article-title":"Patient-reported outcomes in relapsed\/refractory multiple myeloma: A systematic review","volume":"26","author":"Sparano","year":"2018","journal-title":"Support Care Cancer"},{"key":"2021122508044100900_onco13054-bib-0008","author":"Singh","year":"2016"},{"key":"2021122508044100900_onco13054-bib-0009","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12955-018-0953-4","article-title":"A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed\/refractory multiple myeloma: The CLARITY study protocol","volume":"16","author":"Efficace","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"2021122508044100900_onco13054-bib-0010","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1080\/13696998.2017.1421546","article-title":"Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy","volume":"21","author":"Gonzalez-McQuire","year":"2018","journal-title":"J Med Econ"},{"key":"2021122508044100900_onco13054-bib-0011","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1477-7525-7-36","article-title":"Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications","volume":"7","author":"Bharmal","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"2021122508044100900_onco13054-bib-0012","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2005.04.275","article-title":"Patient online self-reporting of toxicity symptoms during chemotherapy","volume":"23","author":"Basch","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122508044100900_onco13054-bib-0013","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"2021122508044100900_onco13054-bib-0014","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"2021122508044100900_onco13054-bib-0015","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"2021122508044100900_onco13054-bib-0016","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1089\/jpm.2014.0089","article-title":"Relationship between onset of pain relief and patient satisfaction with fentanyl pectin nasal spray for breakthrough pain in cancer","volume":"17","author":"Torres","year":"2014","journal-title":"J Palliat Med"},{"key":"2021122508044100900_onco13054-bib-0017","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1007\/s00520-013-1886-4","article-title":"Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer","volume":"21","author":"Hitz","year":"2013","journal-title":"Support Care Cancer"},{"key":"2021122508044100900_onco13054-bib-0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-14-42","article-title":"A longitudinal analysis of patient satisfaction with care and quality of life in ambulatory oncology based on the OUT-PATSAT35 questionnaire","volume":"14","author":"Nguyen","year":"2014","journal-title":"BMC Cancer"},{"key":"2021122508044100900_onco13054-bib-0019","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2147\/PPA.S106629","article-title":"Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: A review of the literature","volume":"10","author":"Eek","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"2021122508044100900_onco13054-bib-0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1634\/theoncologist.6-suppl_4-12","article-title":"Answering patients\u2019 needs: Oral alternatives to intravenous therapy","volume":"6","author":"Borner","year":"2001","journal-title":"The Oncologist"},{"key":"2021122508044100900_onco13054-bib-0021","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/annonc\/mdj044","article-title":"Patients\u2019 preference for administration of endocrine treatments by injection or tablets: Results from a study of women with breast cancer","volume":"17","author":"Fallowfield","year":"2006","journal-title":"Ann Oncol"},{"key":"2021122508044100900_onco13054-bib-0022","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.leukres.2017.05.019","article-title":"Living with the burden of relapse in multiple myeloma from the patient and physician perspective","volume":"59","author":"Hulin","year":"2017","journal-title":"Leukemia Res"},{"key":"2021122508044100900_onco13054-bib-0023","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2008.2003","article-title":"NCCN task force report: Oral chemotherapy","volume":"6","author":"Weingart","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122508044100900_onco13054-bib-0024","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/PPA.S24752","article-title":"A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence","volume":"6","author":"Barbosa","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"2021122508044100900_onco13054-bib-0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00520-013-1956-7","article-title":"Patient satisfaction with service quality as a predictor of survival outcomes in breast cancer","volume":"22","author":"Gupta","year":"2014","journal-title":"Support Care Cancer"},{"key":"2021122508044100900_onco13054-bib-0026","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1200\/JOP.2016.019729","article-title":"Treatment satisfaction and adherence to oral chemotherapy in patients with cancer","volume":"13","author":"Jacobs","year":"2017","journal-title":"J Oncol Pract"},{"key":"2021122508044100900_onco13054-bib-0027","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.20","article-title":"Prospective longitudinal study on quality of life in relapsed\/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment","volume":"7","author":"Leleu","year":"2017","journal-title":"Blood Cancer J"},{"key":"2021122508044100900_onco13054-bib-0028","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clml.2017.12.012","article-title":"Prolonged duration of therapy is associated with improved survival in patients treated for relapsed\/refractory multiple myeloma in routine clinical care in the United States","volume":"18","author":"Hari","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2021122508044100900_onco13054-bib-0029","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/NCC.0b013e3182693522","article-title":"Personal financial effects of multiple myeloma and its treatment","volume":"36","author":"Goodwin","year":"2013","journal-title":"Cancer Nurs"},{"key":"2021122508044100900_onco13054-bib-0030","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1016\/S2352-3026(15)00151-9","article-title":"Financial toxicity in insured patients with multiple myeloma: A cross-sectional pilot study","volume":"2","author":"Huntington","year":"2015","journal-title":"Lancet Haematol"},{"key":"2021122508044100900_onco13054-bib-0031","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clml.2018.01.006","article-title":"Assessing the effect of adherence on patient-reported outcomes and out of pocket costs among patients with multiple myeloma","volume":"18","author":"Gupta","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2021122508044100900_onco13054-bib-0032","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.sapharm.2017.05.009","article-title":"The impact of self- and physician-administered cancer treatment on work productivity and healthcare utilization","volume":"14","author":"Seabury","year":"2018","journal-title":"Res Social Adm Pharm"},{"key":"2021122508044100900_onco13054-bib-0033","first-page":"9","author":"Seal","year":"2016"},{"key":"2021122508044100900_onco13054-bib-0034","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0724","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0724","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/11\/1479\/41917951\/oncolo_24_11_1479.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/11\/1479\/41917951\/oncolo_24_11_1479.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:06:17Z","timestamp":1640419577000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/11\/1479\/6439820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,8,1]]},"published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0724","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11,1]]},"published":{"date-parts":[[2019,8,1]]}}}